Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs

BMC Research Notes

Marjorie Gill¹  Pedro Cortés²  Juan Ávila²  Carolina Torres²  Lidia Rivera²  Isabel Pizarro²  Domingo A Román² 

[1] Oncological Center, Antofagasta Regional Hospital, Antofagasta, Chile;Bioinorganic and Environmental Analytical Chemistry Laboratory, Chemistry Department, Faculty of Basic Science, University of Antofagasta, Antofagasta, Chile

关键词: Inter-element relationships;    Selenium;    Arsenic;    Platinum;    Heavy metal urine analyses;    24-hours urine samples;    Platinum-based drugs chemotherapy;    Cancer;   

Others  :  1166474
DOI  :  10.1186/1756-0500-5-207

 received in 2011-10-08, accepted in 2012-04-30,  发布年份 2012

【 摘 要 】

Background

Arsenic exposure increases the risk of non-cancerous and cancerous diseases. In the Antofagasta region in Chile, an established relationship exists between arsenic exposure and the risk of cancer of the bladder, lung and skin. Platinum-based drugs are first-line treatments, and many works recognise selenium as a cancer-fighting nutrient. We characterised the short-term urinary excretion amounts of arsenic, selenium and platinum in 24-h urine samples from patients with lung cancer and those with cancer other than lung treated with cisplatin or/and carboplatin. As - Se - Pt inter-element relationships were also investigated.

Results

The amounts of platinum excreted in urine were not significantly different between patients with lung cancer and those with other cancers treated with cisplatin, despite the significant variation in platinum amounts supplied from platinum-based drugs. In general, the analytical amounts of excreted selenium were greater than those for arsenic, which could imply that platinum favours the excretion of selenium. For other types of cancers treated with drugs without platinum, excretion of selenium was also greater than that of arsenic, suggesting an antagonist selenium-anti-cancer drug relationship.

Conclusions

Regards the baseline status of patients, the analytical amounts of excreted Se is greater than those for As, particularly, for cisplatin chemotherapy. This finding could imply that for over the As displacement Pt favours the excretion of Se. The analytical amounts of excreted Se were greater than those for As, either with and without Pt-containing drugs, suggesting an antagonist Se-anti-cancer drug relationship. However, it seemed that differences existed between As - Se - Pt inter-element associations in patients treated for lung cancer in comparison with those treated for cancer other than lung. Therefore, knowledge obtained in this work, can contribute to understanding the arsenic cancer mechanism and the As - Se - Pt inter-element association for lung cancer and other types of cancer, which in some cases respond at a linear mathematical model.

【 授权许可】

   
2012 Roman et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

【 参考文献 】

• [1]Selinus O: Medical Geology: an emerging speciality. Terrae. 2004, 1:8-15.
• [2]Selinus O, Alloway JA, Centeno RB, Finkelman RF, Smedley VP: Essential of Medical Geology. Impact of the Natural Environmental on Public Health. Elsevier, U. S. A., London; 2005.
• [3]Madden EF: The role of combined metal interactions in metal carcinogenesis: a review. Rev Environ Heal 2003, 18:91-109.
• [4]Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinnaus C, Selvin S, Liaw J, Smith AH: Fifty - year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 2007, 99:920-928.
• [5]Román DA, Pizarro I, Rivera L, Cámara C, Palacios MA, Gómez MM, Solar C: An approach to the arsenic status in cardiovascular tissues of patients with coronary heart disease. Hum Exp Toxicol 2010, 30:1150-1164.
• [6]Fraser B: Cancer cluster in Chile linked to arsenic contamination. Lancet 2012, 379:603.
• [7]Fernández MI, López JF, Vivaldi B, Coz F: Long - term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure. J Urol 2012, 187:856-861.
• [8]Gordon RB: Production residues in copper technological cycles. Resour Conserv Recycl 2002, 36:87-106.
• [9]Ferreccio C, Sancha AM: Arsenic exposure and its impact on health in Chile. J Health Popul Nutr 2006, 24:164-175.
• [10]Rahman M: International research on arsenic contamination and health. J Health Popul Nutr 2006, 24:123-128.
• [11]Smith AH, Ercumen A, Juan J, Steinmaus CM: Increased lung cancer risks are similar whether arsenic is ingested or inhaled. Journal of Exposure Science and Environmental Epidemiology 2009, 9:343-348.
• [12]Smith A, Marshall G, Yuan Y, Ferreccio C, Liaw J, Von Ehrenstein O, Steinmaus C, Bates M, Selvin S: Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ Health Perspect 2006, 114:293-1296.
• [13]Pasetto M, D’Andrea M, Brandes A, Rossi E, Monfardini S: The development of platinum compound and their possible combination. Critical Reviews in Oncology/Hematology 2006, 60:59-75.
• [14]Su Ch-Ch, Lin Y-Y, Chang T-T, Chiang Ch-T, Chung J-A, Hsu Y-Y, Lian L-B: Incidence of oral cancer in relation to nickel and arsenic concentrations in farm soils of patients’ residential areas in Taiwan. BMC Public Health 2010, 10:67. BioMed Central Full Text
• [15]Duker A, Carranza E, Hale M: Arsenic geochemistry and health. Environ Int 2005, 31:631-641.
• [16]Kelleand L: The resurgence of platinum-based cancer chemotherapy. Nature Reviews 2007, 7:573-584.
• [17]Kalavrouziotis IK, Koukoulakis PH: The environmental impact of the platinum group elements (Pt, Pd, Rh) emitted by the automobile catalyst converters. Water Air Soil Pollut 2009, 196:393-402.
• [18]Kuo MT, Chen HHW, Song IS, Savaraj N, Ishikawa T: The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007, 26:71-83.
• [19]Bharti SK, Singh SK: Recent developments in the field of anticancer metallopharmaceuticals. International Journal of Pharm Tech Research 2009, 1:1406-1420.
• [20]Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RHJ, Wiemer EAC: Drug transporters of platinum - based anticancer agents and their clinical significance. Drug Resistance Updates 2011, 14:22-34.
• [21]Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, Micksche M, Keppler B, Berger W: Resistance against novel anticancer metal compounds: differences and similarities. Drug Resistance Updates 2008, 11:1-16.
• [22]Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK: Collateral damage in cancer chemotherapy: oxidative stress in non-targeted tissues. Mol Interv 2007, 3:147-156.
• [23]Gurney M: How to calculate the dose of chemotherapy. Br J Cancer 2002, 86:1297-1302.
• [24]Mathijssen RHJ, De Jong FA, Loos WJ, Van Der Bol JM, Verweij J, Sparreboom A: Flat - fixed dosing versus body surface area - based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007, 12:913-923.
• [25]Rossman TG, Uddin AN: Selenium prevents spontaneous and arsenite - induced mutagenesis. Int Congr Ser 2004, 1275:173-179.
• [26]Agusa T, Nomura K, Kunito T, Anan Y, Iwata H, Miyazaki N, Tatsukawa R, Tanabe S: Interelement relationships and age –related variation of trace element concentrations in liver of striped dolphins (Stenella coeruleoalba) from Japanese coastal waters. Mar Pollut Bull 2008, 57:807-815.
• [27]Spallholz JE, Boylan LM, Rhaman MM: Environmental hypothesis: is poor dietary selenium intake an underlying factor for arsenicosis and cancer in Bangladesh and West Bengal, India? Sci Total Environ 2004, 323:21-32.
• [28]Zeng H, Uthus EO, Combs GF: Mechanistic aspects of the interaction between selenium and arsenic. J Inorg Biochem 2005, 99:1269-1274.
• [29]Pilsner JR, Hall MN, Liu X, Ahsan H, LLievski V, Stavkovich V, Levy D, Factor-Litvak P, Graziano JH, Gamble MV: Associations of plasma selenium with arsenic and genomic methylation of leukocyte DNA in Bangladesh. Environ Health Perspect 2011, 119:113-118.
• [30]Gromadzinska J, Reszka E, Bruzelius K, Wasowicz W, Akesson B: Selenium and cancer: biomarkers of selenium status and molecular action of selenium supplements. Eur J Nutr 2008, 47:29-50.
• [31]Combs GF, Watts JC, Jackson MI, Johnson LK, Zeng H, Scheett AJ, Uthus EO, Schomburg L, Hoeg A, Hoefig CS, Davis CD, Milner JA: Determinants of selenium status in healthy adults. Nutr J 2011. doi:
• [32]Selenium in health and disease III: Nonendemic selenium - responsive conditions, cancer, and coronary vascular disease. Selenium in Food and Health 2006, 2006:111-133.
• [33]Dodig S, Cepelak I: The facts and controverses about selenium. Acta Pharm 2004, 54:261-276.
• [34]Stone RL, Sood AK, Coleman RL: Collateral damage: toxic effects of targeted anti-angiogenic therapies in ovarian cancer. Lancet Oncol 2010, 11:265-475.
• [35]Pani G, Galeotti T, Chiarugi P: Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Rev 2010, 29:351-378.
• [36]Novotny L, Rauko P, Kombian SB, Edafiogho JO: Selenium as a chemoprotective anti - cancer agent: reality or wishful thinking? Neoplasma 2010, 57:383-391.
• [37]Ledesma ML, Jung-Hynes B, Schmit TL, Kumar R, Mukhtar H, Ahmad N: Selenium and vitamin E for prostate cancer: post - select (Selenium and Vitamin E Cancer Prevention Trial) status. MOL MED 2011, 17:134-143.
• [38]Rayman MP: Selenium and human health. [http://www.thelancet.com] webcite Published online February 29, 2012
• [39]Schrauzer GN: Selenium and selenium - antagonistic elements in nutritional cancer prevention. Crit Rev Biotechnol 2009, 1:7-10.
• [40]Vahter M, Bjorkman L, Goessler W: Concentrations of biomarkers in spot urine samples need adjustment for variation in dilution- comment on: “Distribution of urinary selenium and arsenic among pregnant women exposed to arsenic in drinking water. Environmental Research 2007, 104:312-313.
• [41]Hail N, Cortes M, Drake EN, Spallholz JE: Cancer chemoprevention: a radical perspective. Free Radical Biology & Medicine 2008, 45:97-110.
• [42]Gerl A, Schierl R: Urinary excretion of platinum in chemotherapy - treated long - term survivors of testicular cancer. Acta Oncologica 2000, 4:519-522.
• [43]Klein AV, Hambley TW: Platinum drug distribution in cancer cells and tumors. Chem Rev 2009, 109:4911-4920.
• [44]Fletcher JI, Haber M, Henderson J, Norris MD: ABC transporters in cancer: more than just drug efflux pumps. Perspectives 2010, 10:147-156.
• [45]Welz B, Melcher M: Decomposition of marine biological tissues for determination of arsenic, selenium and mercury using hydride-generation and cold - vapor atomic absorption spectrometry. Anal Chem 1985, 2:427-431.
• [46]Husdan H, Rapoport A: Estimation of Creatinine by the Jaffe Reaction, A comparison of Three Methods. Metabolic-Renal Unit and the department of Biochemistry, Toronto Western Hospital, and the department of medicine and of Pathological Chemistry, University of Toronto, Toronto Canada; 1967.
• [47]Rafey M, Lipkowitz M: How accurate are formulas that calculate creatinine clearance? Nature Clinical Practice Urology 2007, 4:188-189.
• [48]Department of Health and Human Services Food and Drug Administration: Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing and Labeling. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER), U.S; 1998.
• [49]Apostoli P: Elements in environmental and occupational medicine. Journal of Chromatography B 2002, 778:63-97.
• [50]Kapustka LA, Clements WH, Ziccardi L, Paquin PR, Sprenger M, Wall D: Issue paper on the ecological effects of metals. U.S. Environmental Protection Agency, Washington DC; 2004:1-74.
• [51]Obhodas J, Tucak-Zoric S, Kutle A, Valkovic V: Indications for synergetic and antagonistic effects between trace elements in the environment to human health. Coll Antropol 2007, 31:209-219.
• [52]Franzle S, Markert B: From the biological system of elements to reasons of fractionation and element use. Metals in Biomass 2007, 14:404-413.
• [53]Abrahams PW, Entwistle JA, Dodgshon RA: The ben lawers historic landscape project: simultaneous multi - element analysis of former settlement and arable soils by X - ray fluorescence spectrometry. J Archaeol Method Theory 2010, 17:231-248.
• [54]Momcilovic B, Prejac J, Brundic S, Morovic S, Skalny AV, Mimica N, Drmic S: An essay on human and elements, multielement profiles, and depression. Translational Neuroscience 2010, 4:322-334.
• [55]Dilda PJ, Hogg PJ: Arsenical - based cancer drugs: cancer treatment. Reviews 2007, 33:542-564.
• [56]Navarro Silvera SA, Rohan TE: Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 2007, 18:7-27.
• [57]Pasha Q, Malik S, Shah MH: Statistical analysis of trace metals in the plasma of cancer patients versus controls. Journal of Hazardous Materials 2008, 153:1215-1221.
• [58]Florea AM, Busselberg D: Metals and breast cancer: risk factors or healing agents? Journal of Toxicology
• [59]Committee on Research Priorities for Earth Science and Public Health: Hearth Materials and Health. Research Priorities for Earth Science and Public Health. National Research Council and Institute of Medicine of the National Academies, The National Academies Press Washington D.C; 2007:188.
• [60]Barraclough LH, Field C, Wieringa G, Swindell R, Livsey JE, Davidson SE: Estimation of renal function - what is appropriate in cancer patients? Clinical Oncology 2008, 20:721-726.
• [61]Sinkeler SJ, Visser FW, Krikken JA, Stegeman CA, van der Heide JJ Homan, Navis G: Higher body mass index is associated with higher fractional creatinine excretion in healthy subjects. Nephrol Dial Transplant 2011, 10:1-8.
• [62]Planet G: Comparison of creatinina clearance estimates with routine measured clearance. Clinical Biochemistry 2007, 40:124-127.
• [63]Barr DB, Wilder LC, Caudill SP, González AJ, Needham LL, Pirkle JL: Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 2005, 113:192-200.
• [64]Rivera L, Ávila J, Morales T, Cortés P, Román D, Vergara L: Distribución de elementos traza y metales pesados en tejidos placentarios de recién nacidos normales (RNN). Enfoque analítico multimetálico. Versión en disco compacto, VIII Encuentro de Química Analítica Ambiental, Sociedad Chilena de Química, Universidad Arturo Prat, Iquique, Chile; 2006.
• [65]Pizarro I, Román D, Ávila J, Morales T, Cortés P, Solar C: Status analítico bioinorgánico de elementos traza en tejidos cardiovasculares de pacientes sometidos a cirugía cardiaca. Versión en disco compacto, VIII Encuentro de Química Analítica Ambiental, Sociedad Chilena de Química, Universidad Arturo Prat, Iquique, Chile; 2006.
• [66]Valenzuela OL, Borja-Aburto VH, García-Vargas GG, Cruz-González MB, García-Montalvo EA, Calderón-Aranda ES, Del Razo LM: Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 2005, 113:250-254.
• [67]Cavar S, Bosnjak Z, Klapec T, Barisic K, Cepelak I, Jurasovic J, Milic M: Blood selenium, glutathione peroxidase activity and antioxidant supplementation of subjects exposed to arsenic via drinking water. Environmental Toxicology and Pharmacology 2010, 29:138-143.
• [68]Oster O, Pellwitz W: The renal excretion of selenium. Biol Trace Elem Res 1990, 24:119-146.
• [69]Zeiner M, Ovari M, Zaray G, Steffan I: Selected urinary metal reference concentrations of the Viennese population - urinary metal reference values (Vienna). Journal of Trace Elements in Medicine and Biology 2006, 20:240-244.
• [70]De Mondragón MC, Jaffé WG: Selenio en alimentos y en orina de escolares de diferentes zonas de Venezuela. Separata de Archivos Latinoamericanos de Nutrición 1971, 21:185-195.
• [71]Forina M, Armanino C, Raggio V: Clustering with dendrograms on interpretation variables. Analytica Chimica Acta 2002, 454:13-19.
• [72]Pletnev I, Zernov V: Classification of metal ions according to their complexing properties: a data - driven approach. Analytica Chimica Acta 2002, 455:131-142.
• [73]Zachara B, Salak A, Koterska D, Manitius J, Wasowicz W: Selenium and glutathione peroxidases in blood of patients with different stages of chronic renal failure. J Trace Elem Med Biol 2004, 17:291-299.
• [74]Thompson LA, Lawson AP, Sutphin SD, Steinke D, Adams VR: Description of current practices of empiric chemotherapy dose adjustment in obese adult patients. Journal of Oncology Practice 2010, 6:141-145.
• [75]Yuan Y, Marshall G, Ferreccio C, Steinmaus C, Selvin S, Liaw J, Bates MN, Smith AH: Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic - exposed region II of Chile from 1950 to 2000. Am J Epidemiol 2007, 166:1381-1391.
• [76]Andrew AS, Burgess JL, Meza MM, Demidenko E, Waugh MG, Hamilton JW, Karagas MR: Arsenic exposure is associated with decreased DNA repair in vitro and individuals exposed to drinking water arsenic. Environ Health Perspect 2006, 114:1193-1198.
• [77]Ren X, Aleshin M, Jo WJ, Dills R, Kalman DA, Vulpe CD, Smith MT, Zhang L: Involvement of N - 6 adenine - specific DNA methyltransferase 1 (N6AMT1) in arsenic biomethylation and its role in arsenic - induced toxicity. Environ Health Perspect 2011, 119:771-777.
• [78]Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L: An emerging role for epigenetic deregulation in arsenic toxicity and carcinogenesis. Environ Health Perspect 2011, 119:11-19.
• [79]Bozhkow A, Padalko V, Dlubovskaya V, Menzianova N: Resistance to heavy metal toxicity in organisms under chronic exposure. Indian Journal of Experimental Biology 2010, 48:679-696.
• [80]Hou L, Wang D, Baccarelli A: Environmental chemicals and micro RNAs. Mutation Research 2011. Article in press
• [81]Hanekamp JC: Micronutrients, hormesis and the aptitude for the maturation of regulation. Am J Pharm & Toxicol 2008, 3:144-151.
• [82]Marmiroli N, Maestri E: Health Implications of Trace Elements in the Environment and the Food Chain. In Trace Elements as Contaminants and Nutrients: Consequences in Ecosystems and Human Health. Edited by Prasad MNV. Wiley, USA, Canada; 2008:23-53.
• [83]Pearson RG (Ed): Chemical Hardness. Applications from Molecules to Solids. Wiley, USA, Canada; 1997.